Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston May 19, 2023 8:43am
238 Views
Post# 35456102

RE:Hot off the press!

RE:Hot off the press!

While some were complaining recently that management was incompetent and lacking transparency despite all the info./roadmap we got since Jan. 3rd, this interview was already planned well in advance.

Of course, such events cannot be disclosed in advance.   And one has to understand that we're involved in a very conservative industry driven by data.  So very difficult to convince.  

Being humble about our advances is what this industry requires.  Trumpeting/claiming in advance that BDT or AA has been submitted is something TLT cannot do, and the industry and regulatory bodies would not accept/tolerate that as it could be perceived like arrogance.

This industry likes discreet behaviors.  Not splashes.  Let them decide. Let them be the judges.  And TLT management clearly understand that.  That's why they're doing things like they do.  They understand their audience; the urologist community.

Management has financial skin in the game.  But most of all, it's their project and they want to bring it to fruition.  So far, they have delivered.  The valuation will fix itself in due time, given that the right things have been done in the the right order, at the right time, without cutting corners.

On our side, with these events so far, we are legitimate to be extremely confident with what lies ahead.


______________


 

Hot off the press!

https://www.urotoday.com/video-lectures/aua-2023/video/mediaitem/3397-promising-developments-in-the-theralase-project-for-bcg-unresponsive-bladder-cancer-girish-kulkarni.html

 

Hot off the press!

https://www.urotoday.com/video-lectures/aua-2023/video/mediaitem/3397-promising-developments-in-the-theralase-project-for-bcg-unresponsive-bladder-cancer-girish-kulkarni.html


<< Previous
Bullboard Posts
Next >>